Five Percent Monolaurin Vaginal Gel for the Treatment of Bacterial Vaginosis: A Randomized Placebo-Controlled Trial
Conclusions
Monolaurin was no more clinically or microbiologically effective than placebo in curing BV. Future research should explore whether monolaurin may be used to increase Lactobacilli species. (Source: Journal of Lower Genital Tract Disease)
Source: Journal of Lower Genital Tract Disease - June 23, 2020 Category: OBGYN Tags: Vaginal Source Type: research
A single-arm clinical trial investigating the effectiveness of a non-hormonal, hyaluronic acid-based vaginal moisturizer in endometrial cancer survivors.
CONCLUSION: The HLA-based gel improved vulvovaginal health and sexual function of endometrial cancer survivors in perceived symptoms and clinical exam outcomes. HLA administration 1-2×/week is recommended for women in natural menopause; a 3-5×/week schedule appears more effective for symptom relief in cancer survivors.
PMID: 32522420 [PubMed - as supplied by publisher] (Source: Gynecologic Oncology)
Source: Gynecologic Oncology - June 7, 2020 Category: Cancer & Oncology Authors: Carter J, Goldfarb S, Baser RE, Goldfrank DJ, Seidel B, Milli L, Saban S, Stabile C, Canty J, Gardner GJ, Jewell EL, Sonoda Y, Kollmeier MA, Alektiar KM Tags: Gynecol Oncol Source Type: research
Development of Multipurpose Technologies Products for Pregnancy and STI Prevention; update on polyphenylene carboxymethylene MPT gel development.
We present the case for developing simple non-hormonal vaginal products that women can use when needed, ideally products that are multipurpose and offer both contraception and sexually transmitted disease protection. Gel-based vaginal products are particularly well-suited for this purpose. Gels are easy to use, highly acceptable to many women, and can be safely formulated to enhance natural vaginal defenses against infection. However, the development of a new chemical entity for this application faces significant technical and regulatory hurdles. These challenges and our solutions are described for polyphenylene carboxymet...
Source: Biology of Reproduction - May 28, 2020 Category: Reproduction Medicine Authors: Weitzel M, North BB, Waller D Tags: Biol Reprod Source Type: research
A Phase II Prospective, Randomized, Double-Blind, Placebo-Controlled and Multicenter Clinical Trial to Assess the Safety of 0.005% Estriol Vaginal Gel in Hormone Receptor-Positive Postmenopausal Women With Early Stage Breast Cancer in Treatment With Aromatase Inhibitor in the Adjuvant Setting.
CONCLUSION: Ultralow-dose 0.005% estriol vaginal gel did not significantly influence estrogens, FSH, and LH levels in women with breast cancer receiving NSAI. A transient negligible absorption of estriol and a nonsignificant variation of FSH after 12 weeks were observed. These findings provide confidence for the safe use of 0.005% estriol vaginal gel in women with breast cancer with an indication for treatment with vaginal estrogens.
PMID: 32459035 [PubMed - as supplied by publisher] (Source: The Oncologist)
Source: The Oncologist - May 26, 2020 Category: Cancer & Oncology Authors: Sánchez-Rovira P, Hirschberg AL, Gil-Gil M, Bermejo-De Las Heras B, Nieto-Magro C Tags: Oncologist Source Type: research
The effect of oxytocin vaginal gel on vaginal atrophy in postmenopausal women: a randomized controlled trial
This study aimed to evaluate the effect of oxytocin vaginal gel on vaginal atrophy among postmenopausal women. (Source: BMC Women's Health)
Source: BMC Women's Health - May 19, 2020 Category: OBGYN Authors: Ilnaz Zohrabi, Parvin Abedi, Somayeh Ansari, Elham Maraghi, Nader Shakiba Maram and Gholamreza Houshmand Tags: Research article Source Type: research
Efficacy and safety of ultra-low dose 0.005% estriol vaginal gel for the treatment of vulvovaginal atrophy in postmenopausal women with early breast cancer treated with nonsteroidal aromatase inhibitors: a phase II, randomized, double-blind, placebo-controlled trial
Conclusions:
Ultra-low dose 0.005% estriol vaginal gel showed efficacy in improving the symptoms and signs of vulvovaginal atrophy. These results, together with minimal oscillations in hormonal levels throughout the treatment, support the use of ultra-low dose 0.005% estriol vaginal gel as a treatment option for vulvovaginal atrophy in women with breast cancer receiving NSAIs with an indication for treatment with vaginal estrogens.
Video Summary:http://links.lww.com/MENO/A531. (Source: Menopause)
Source: Menopause - May 1, 2020 Category: OBGYN Tags: Original Studies Source Type: research
Glycine Max (L.) Merr isoflavone gel improves vaginal vascularization in postmenopausal women.
Conclusion: The results showed that local administration of Glycine max (L.) Merr isoflavone gel promoted a significant improvement in the number of blood vessels in the vaginal tissue of postmenopausal women.
PMID: 32338067 [PubMed - as supplied by publisher] (Source: Climacteric)
Source: Climacteric - April 26, 2020 Category: Geriatrics Authors: Lima SMRR, Honorato JV, Silva MALG Tags: Climacteric Source Type: research
Comparing Foley Catheter to Prostaglandins for Cervical Ripening in Multiparous Women.
CONCLUSION: In multiparous women requiring cervical ripening, all methods of cervical ripening have a similar success rate. However, the use of a PGE2-CR insert is associated with a considerably longer interval to delivery compared with a Foley catheter or PGE2 gel.
PMID: 32005633 [PubMed - as supplied by publisher] (Source: Journal of Obstetrics and Gynaecology Canada : JOGC)
Source: Journal of Obstetrics and Gynaecology Canada : JOGC - February 2, 2020 Category: OBGYN Tags: J Obstet Gynaecol Can Source Type: research
Biocompatibility and zinc release testing of a zinc-containing vaginal gel
Conclusions:
The zinc-containing (20 μM) vaginal gel was not toxic. The release of zinc is rapid from the vaginal gel. Zinc permeated rapidly through the vaginal epithelial cell layers. (Source: Menopause)
Source: Menopause - January 31, 2020 Category: OBGYN Tags: Original Studies Source Type: research
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis
ConclusionThese results support a role for Astodrimer 1% Gel as an effective, safe and well-tolerated treatment for women with bacterial vaginosis. (Source: European Journal of Obstetrics and Gynecology and Reproductive Biology)
Source: European Journal of Obstetrics and Gynecology and Reproductive Biology - November 29, 2019 Category: OBGYN Source Type: research
Proof of concept study to evaluate the efficacy of a novel thermosetting bioadhesive 2% clindamycin phosphate vaginal gel in the treatment bacterial vaginosis
The objective of the study was to test the efficacy and safety of a novel single dose of a thermosetting bioadhesive 2% clindamycin phosphate vaginal gel for the treatment of bacterial vaginosis (BV) in a single center, single arm, open-label study. (Source: American Journal of Obstetrics and Gynecology)
Source: American Journal of Obstetrics and Gynecology - November 29, 2019 Category: OBGYN Authors: A. Dupree, H. Alur Tags: IDSOG Abstract Source Type: research
Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis
The objective of these studies was to confirm the efficacy and safety of Astodrimer 1% Gel for treatment of BV. (Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology)
Source: European Journal of Obstetrics, Gynecology, and Reproductive Biology - November 27, 2019 Category: OBGYN Authors: Steven E. Chavoustie, Belvia A. Carter, Arthur S. Waldbaum, Gilbert G.G. Donders, Klaus H. Peters, Jane R. Schwebke, Jeremy R.A. Paull, Clare F. Price, Alex Castellarnau, Philip McCloud, George R. Kinghorn Tags: Full length article Source Type: research
Social harms in female-initiated HIV prevention method research: state of the evidence
Conclusion:
Measurement and screening for social harms is an important component of conducting ethical research of novel HIV prevention methods. To date, social harm incidence reported in microbicide trials has been relatively low ( (Source: AIDS)
Source: AIDS - November 5, 2019 Category: Infectious Diseases Tags: Epidemiology and Social Source Type: research
The Underlying Mechanism of 3-Hydroxyphthalic Anhydride-Modified Bovine Beta-Lactoglobulin to Block Human Papillomavirus Entry Into the Host Cell
We have previously demonstrated that 3-hydroxyphthalic anhydride (3HP)-modified bovine beta-lactoglobulin (3HP-β-LG) is highly effective in inhibiting entry of pseudovirus (PsV) of high- and low-risk human papillomavirus (HPV) into the target cell. Intravaginally applied 3HP-β-LG-containing vaginal gel could significantly inhibit HPV infection and reduce viral load in the cervical region. However, we still do not understand the underlying molecular mechanism by which 3HP-β-LG is able to inhibit HPV infection. Here, though, we showed that 3HP-β-LG did not inactivate HPV PsV, but rather blocked entry of HPV PsV into the ...
Source: Frontiers in Microbiology - September 25, 2019 Category: Microbiology Source Type: research
Acceptability and performance of a nonwoven device for vaginal drug delivery among women and their male partners in KwaZulu-Natal, South Africa.
Conclusions: Data are promising for further development of this nonwoven device for vaginal drug delivery. Plain English summary Multipurpose prevention technologies (MPTs) that protect against HIV and sexually transmitted infections (STIs) are urgently needed. A variety of vaginal gel-based products are actively being researched; however, these products can often have challenges with vaginal leakage and retention. This research investigates the acceptability and performance of a nonwoven device to deliver vaginal gel formulations. The gel used in this study was a currently available marketed personal lubricant. In South A...
Source: The European Journal of Contraception and Reproductive Health Care - September 12, 2019 Category: Reproduction Medicine Authors: Hart CW, Joanis C, Hartmann M, Milford C, Smit J, Beksinska M, Rambally-Greener L, Pienaar J, Mabude Z, Butterworth GAM, Sokal D, Jenkins D Tags: Eur J Contracept Reprod Health Care Source Type: research
